Who are BTV100 High dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LONCASTUXIMAB TESIRINE, Uplizna, BLINATUMOMAB, Blincyto, IL-2 pre-treated CD19 cells, MONJUVI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/btv100-high-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

BTV100 High dose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BTV100 High dose (BTV100 High dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD19-targeting monoclonal antibody. Area: Oncology.

phase 2 CD19-targeting monoclonal antibody CD19 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BTV100 High dose (BTV100 High dose) — BioTheraVision, Inc.. BTV100 is a monoclonal antibody targeting CD19.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BTV100 High dose TARGET	BTV100 High dose	BioTheraVision, Inc.	phase 2	CD19-targeting monoclonal antibody	CD19
LONCASTUXIMAB TESIRINE	LONCASTUXIMAB TESIRINE		marketed	Antibody-Drug Conjugate (ADC)	CD19	2021-01-01
Uplizna	INEBILIZUMAB	Viela Bio	marketed	CD19-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD19	2020-01-01
BLINATUMOMAB	BLINATUMOMAB		marketed		CD19, CD3	2014-01-01
Blincyto	blinatumomab	Amgen	marketed	Bispecific CD19-directed CD3-directed T Cell Engager	B-lymphocyte antigen CD19	2014-01-01
IL-2 pre-treated CD19 cells	IL-2 pre-treated CD19 cells	jiangjingting	marketed	Adoptive cell therapy	CD19
MONJUVI	TAFASITAMAB-CXIX	MORPHOSYS US INC	marketed		B-lymphocyte antigen CD19

Recent regulatory actions (last 90 days)

2026-02-20 — LONCASTUXIMAB TESIRINE · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD19-targeting monoclonal antibody class)

BioTheraVision, Inc. · 2 drugs in this class
Polish Adult Leukemia Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BTV100 High dose — Competitive Intelligence Brief. https://druglandscape.com/ci/btv100-high-dose. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab